Palliative radiotherapy to dominant symptomatic lesion in patients with hormone refractory prostate cancer (PRADO)

Overview of attention for article published in Radiation Oncology, January 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (64th percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

So far, Altmetric has seen 8 X posts from 8 X users, with an upper bound of 8,845 followers.

Palliative radiotherapy to dominant symptomatic lesion in patients with hormone refractory prostate cancer (PRADO). https://t.co/G3CiNpVOYU

RT @JoaquinJCabrera: Palliative radiotherapy to dominant symptomatic lesion in patients with hormone refractory prostate cancer (PRADO) #ra…

RT @JoaquinJCabrera: Palliative radiotherapy to dominant symptomatic lesion in patients with hormone refractory prostate cancer (PRADO) #ra…

RT @JoaquinJCabrera: Palliative radiotherapy to dominant symptomatic lesion in patients with hormone refractory prostate cancer (PRADO) #ra…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.